Published in J Clin Endocrinol Metab on July 11, 2014
Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev (2014) 1.07
Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. Endocr Relat Cancer (2015) 0.86
An Optimized Method of Metabolite Extraction from Formalin-Fixed Paraffin-Embedded Tissue for GC/MS Analysis. PLoS One (2015) 0.86
Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications. Neoplasia (2015) 0.86
SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery. J Natl Cancer Inst (2016) 0.81
Oxygen concentration controls epigenetic effects in models of familial paraganglioma. PLoS One (2015) 0.80
Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. J Natl Cancer Inst (2016) 0.79
Pheochromocytoma: The First Metabolic Endocrine Cancer. Clin Cancer Res (2016) 0.78
Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. Neoplasia (2016) 0.76
(18)F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L. Eur J Nucl Med Mol Imaging (2016) 0.76
Utility of the succinate: Fumarate ratio for assessing SDH dysfunction in different tumor types. Mol Genet Metab Rep (2016) 0.75
Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. Langenbecks Arch Surg (2017) 0.75
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell (2005) 9.33
Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature (2013) 5.44
Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet (2005) 4.12
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med (2012) 3.30
SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell (2013) 3.24
Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst (2008) 2.89
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68
Next-generation sequencing for clinical diagnostics. N Engl J Med (2013) 2.63
Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res (2003) 2.29
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene (2011) 1.87
The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One (2009) 1.75
Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum Mol Genet (2007) 1.67
An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res (2012) 1.62
Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer (2011) 1.49
Simultaneous liquid chromatography tandem mass spectrometric determination of urinary free metanephrines and catecholamines, with comparisons of free and deconjugated metabolites. Clin Chim Acta (2013) 1.46
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood (2013) 1.41
The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab (2013) 1.36
Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. Hum Mol Genet (2010) 1.33
Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma. PLoS One (2011) 1.24
The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Eur J Endocrinol (2011) 1.22
Large germline deletions of mitochondrial complex II subunits SDHB and SDHD in hereditary paraganglioma. J Clin Endocrinol Metab (2004) 1.14
Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. Endocr Pathol (2012) 1.14
Cancer. Puzzling patterns of predisposition. Science (2009) 1.09
A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2013) 1.02
Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings. Endocrinology (2013) 1.00
A new specific succinate-glutamate metabolomic hallmark in SDHx-related paragangliomas. PLoS One (2013) 0.96
Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: a possible hot spot? Genes Chromosomes Cancer (2006) 0.95
Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma. Clin Cancer Res (2013) 0.90
Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. Neuro Oncol (2013) 0.90
Identification of a signaling axis HIF-1α/microRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas. J Clin Endocrinol Metab (2012) 0.86
Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Ann Clin Biochem (2013) 0.84
The management of head-and-neck paragangliomas. Endocr Relat Cancer (2013) 0.82
Mitochondrial function and content in pheochromocytoma/paraganglioma of succinate dehydrogenase mutation carriers. Endocr Relat Cancer (2012) 0.82
Pitfalls in genetic analysis of pheochromocytomas/paragangliomas-case report. J Clin Endocrinol Metab (2014) 0.80
Where metabolism meets oncogenesis: another false lead? Lancet Oncol (2010) 0.77
A human gut microbial gene catalogue established by metagenomic sequencing. Nature (2010) 43.63
The sequence and de novo assembly of the giant panda genome. Nature (2009) 15.76
Phaeochromocytoma. Lancet (2005) 8.73
The genome of the cucumber, Cucumis sativus L. Nat Genet (2009) 8.19
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
Resequencing of 31 wild and cultivated soybean genomes identifies patterns of genetic diversity and selection. Nat Genet (2010) 5.20
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA (2004) 4.52
Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension (2006) 4.20
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74
Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab (2005) 3.32
Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab (2007) 3.25
Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol (Oxf) (2013) 3.12
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer (2009) 2.98
Evidence for two types of brown adipose tissue in humans. Nat Med (2013) 2.97
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas (2010) 2.84
Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet (2013) 2.83
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Genomic comparison of the ants Camponotus floridanus and Harpegnathos saltator. Science (2010) 2.78
Primary hypertension and neurovascular compression: a meta-analysis of magnetic resonance imaging studies. J Neurosurg (2011) 2.75
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol (2011) 2.75
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 2.72
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet (2007) 2.64
Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol (2007) 2.60
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2009) 2.51
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol (2010) 2.42
Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab (2007) 2.41
Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension (2012) 2.31
Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. Arch Pathol Lab Med (2014) 2.31
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet (2011) 2.29
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet (2010) 2.23
Historical variations in mutation rate in an epidemic pathogen, Yersinia pestis. Proc Natl Acad Sci U S A (2012) 2.22
Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem (2006) 2.20
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. Eur J Endocrinol (2014) 2.13
Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov (2013) 2.11
Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab (2003) 2.08
High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab (2006) 2.04
Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab (2004) 2.00
Central nervous system imprinting of the G protein G(s)alpha and its role in metabolic regulation. Cell Metab (2009) 1.98
The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int (2008) 1.94
New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf) (2009) 1.92
The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med (2007) 1.91
Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther (2003) 1.87
Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab (2011) 1.86
Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J (2005) 1.80
Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst (2012) 1.78
Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int (2012) 1.77
Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension (2013) 1.76
Cardiovascular manifestations of phaeochromocytoma. J Hypertens (2011) 1.74
PupaSNP Finder: a web tool for finding SNPs with putative effect at transcriptional level. Nucleic Acids Res (2004) 1.74
The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer (2010) 1.73
Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab (2003) 1.70
Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev (2004) 1.69
11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab (2002) 1.68
Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol (2010) 1.67
Metagenome-wide analysis of antibiotic resistance genes in a large cohort of human gut microbiota. Nat Commun (2013) 1.65
Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol (2009) 1.65
Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken) (2010) 1.64
Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation (2009) 1.63
Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. J Hypertens (2007) 1.61
Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise. J Clin Endocrinol Metab (2004) 1.60
Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency. J Clin Endocrinol Metab (2002) 1.57
The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet (2009) 1.57